Ask AI

Evolving Role of TROP-2–Directed ADCs as First-line Therapy in TNBC

Text Module
Text Module Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: August 28, 2026

Expiration: February 27, 2027

See Activity Collection

Read this text module to learn about recent advances in the treatment of metastatic triple-negative breast cancer (mTNBC), with a focus on the evolving role of sacituzumab govitecan and datopotamab deruxtecan as TROP-2–directed antibody–drug conjugates (ADCs) in the first-line setting. Learners will examine the clinical evidence supporting newly approved therapies, compare key phase III trial designs and efficacy and safety data, and explore practical considerations for treatment selection, supportive care planning, and integration of these agents into contemporary treatment algorithms. The activity also highlights emerging ADCs, targeted therapies, and combination strategies that may further expand treatment options for patients with mTNBC.

1L TROP2 ADCs in TNBC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with breast cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 58-year-old patient presents with newly diagnosed unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Biomarker testing shows estrogen receptor/progesterone receptor–negative disease, HER2 0, PD-L1 combined positive score (CPS) 20, and no germline BRCA1/2 pathogenic variant. The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 1, no history of autoimmune disease, and no prior systemic therapy for unresectable or metastatic disease.

Which first-line treatment plan best incorporates current evidence for TROP-2–directed ADC therapy for this patient?